Table 2.
Substrate | Parameter | C | G |
---|---|---|---|
Respiration | |||
Pyr/mal | State II | 12.8 ± 1.4 | 16.9 ± 2.0 |
State III | 129.6 ± 20.7 | 156.7 ± 18.8 | |
State IV | 14.8 ± 2.3 | 18.4 ± 1.2 | |
RCR | 8.9 ± 1.1 | 8.4 ± 0.5 | |
PC/mal | State II | 18.9 ± 5.0 | 15.4 ± 1.9 |
State III | 108.3 ± 23.3 | 93.3 ± 16.4 | |
State IV | 16.9 ± 3.6 | 15.1 ± 1.0 | |
RCR | 6.3 ± 0.5 | 6.1 ± 0.9 | |
ROS production | |||
Pyr/mal | State II | 160 ± 15 | 152 ± 17 |
+Rotenone | 315 ± 34 | 309 ± 54 | |
+Antimycin A | 529 ± 67 | 462 ± 75 | |
PC/mal | State II | 131 ± 15 | 134 ± 11 |
+Rotenone | 240 ± 16 | 222 ± 21 | |
+Antimycin A | 651 ± 79 | 522 ± 54* | |
ROS/State II | |||
Pyr/mal | State II | 12.8 ± 1.0 | 9.1 ± 0.8* |
PC/mal | State II | 8.2 ± 1.2 | 9.1 ± 1.1 |
Values are means ± SE. The number of experiments was 6 per group: C, control; G, hearts perfused with GIK solution during ischemia and reperfusion. The results of state II, III, and IV respiration rates are expressed in ng atoms O2 · min−1 · mg mitochondrial protein−1, reactive oxygen species (ROS) production is expressed in pmol · min−1 · mg mitochondrial protein−1, and the ROS/state II ratio is expressed in pmol/ng atoms O2. Pyr/mal, pyruvate/malate; PC/mal, palmitoylcarnitine/malate; RCR, respiratory control ratio.
P < 0.05 indicates a significant difference.